Highlights
Key Investment Highlights
A snapshot of the Key Investment Highlights associated with Noctura and their EIS-eligible investment opportunity.

EXPERIENCED
TEAM
An experienced leadership team and an advisory board of leading experts in ophthalmology from around the globe.

INNOVATIVE
PRODUCT
The sleep mask emits a gentle, low-level light to reduce oxygen demand in the eye, preventing hypoxia, a key factor in diabetic eye disease.

DEFENSIBLE
IP
Four filed and registered patents in place, providing significant value to the Company.

ACQUISITION OPPORTUNITY
The Noctura sleep mask product complements the diabetic treatments of major pharmaceutical companies, meaning the Company could be a prime target for a strategic acquisition.

VAST MARKET
OPPORTUNITY
With 153 million sufferers of diabetic eye disease worldwide, Noctura already has regulatory approval for 33% of the global patient population.

BETTER THAN
ALTERNATIVES
A non-invasive therapy that can be administered much earlier than alternative treatments, which are often highly invasive and costly.

IMPACT-DRIVEN
INVESTMENT
Funding a business dedicated to improving the quality of life for people worldwide.

TARGET
RETURNS
Target returns of 9.52x. Your capital is at risk and target returns are not guaranteed.